U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C21H21FN8O
Molecular Weight 420.4428
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BAY-41-8543

SMILES

NC1=NC(=NC(N)=C1N2CCOCC2)C3=NN(CC4=CC=CC=C4F)C5=NC=CC=C35

InChI

InChIKey=AQYFUZRYBJBAGZ-UHFFFAOYSA-N
InChI=1S/C21H21FN8O/c22-15-6-2-1-4-13(15)12-30-21-14(5-3-7-25-21)16(28-30)20-26-18(23)17(19(24)27-20)29-8-10-31-11-9-29/h1-7H,8-12H2,(H4,23,24,26,27)

HIDE SMILES / InChI

Molecular Formula C21H21FN8O
Molecular Weight 420.4428
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

BAY 41-8543 (2-[1-[(2-fuorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5(4-morpholinyl)-4,6-pyrimidinediamine) is s potent nitric oxide (NO)-independent stimulator of soluble guanylate cyclase (sGC). BAY 41-8543 manifested both antiplatelet effect and vasodilatation. It has the potential of being a unique clinical utility for the treatment of cardiovascular diseases.

Approval Year

PubMed

PubMed

TitleDatePubMed
Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies.
2002 Jan
Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vivo studies.
2002 Jan
Sustained soluble guanylate cyclase stimulation offsets nitric-oxide synthase inhibition to restore acute cardiac modulation by sildenafil.
2008 Aug
Patents

Patents

Sample Use Guides

In anaesthetized dogs, intravenous injections of BAY 41-8543 (3 - 100 microg kg(-1)) caused a dose-dependent decrease in blood pressure and cardiac oxygen consumption as well as an increase in coronary blood flow and heart rate. In anaesthetized normotensive rats, BAY 41-8543 produced a dose-dependent and long-lasting blood pressure lowering effect after intravenous (3 - 300 microg kg(-1)) and oral (0.1 - 1 mg kg(-1)) administration. A dose-dependent and long-lasting decrease in blood pressure was also observed in conscious spontaneously hypertensive rats with a threshold dose of 0.1 mg kg(-1) p.o. After 3 mg kg(-1) the antihypertensive effect lasted for nearly 24 h.
Route of Administration: Other
In vitro, BAY 41-8543 is a potent relaxing agent of aortas, saphenous arteries, coronary arteries and veins with IC(50)-values in the nM range. In the rat heart Langendorff preparation, BAY 41-8543 potently reduces coronary perfusion pressure from 10(-9) to 10(-6) g ml(-1) without any effect on left ventricular pressure and heart rate. BAY 41-8543 is effective even under nitrate tolerance conditions proved by the same vasorelaxing effect on aortic rings taken either from normal or nitrate-tolerant rats. BAY 41-8543 is a potent inhibitor of collagen-mediated aggregation in washed human platelets (IC(50)=0.09 microM).
Substance Class Chemical
Created
by admin
on Sat Dec 16 09:44:18 GMT 2023
Edited
by admin
on Sat Dec 16 09:44:18 GMT 2023
Record UNII
323T2C09SG
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BAY-41-8543
Common Name English
4,6-PYRIMIDINEDIAMINE, 2-(1-((2-FLUOROPHENYL)METHYL)-1H-PYRAZOLO(3,4-B)PYRIDIN-3-YL)-5-(4-MORPHOLINYL)-
Systematic Name English
Code System Code Type Description
FDA UNII
323T2C09SG
Created by admin on Sat Dec 16 09:44:18 GMT 2023 , Edited by admin on Sat Dec 16 09:44:18 GMT 2023
PRIMARY
CAS
256498-66-5
Created by admin on Sat Dec 16 09:44:18 GMT 2023 , Edited by admin on Sat Dec 16 09:44:18 GMT 2023
PRIMARY
EPA CompTox
DTXSID10180342
Created by admin on Sat Dec 16 09:44:18 GMT 2023 , Edited by admin on Sat Dec 16 09:44:18 GMT 2023
PRIMARY
PUBCHEM
9953906
Created by admin on Sat Dec 16 09:44:18 GMT 2023 , Edited by admin on Sat Dec 16 09:44:18 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY